Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2023 1
2024 8
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Rose AM, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg HD, Bolt Botnen A, O'Doherty MG, Pozo F, Hameed SS, Andrews N, Hamilton M, Trebbien R, Lauenborg Møller K, Marques DF, Murphy S, McQueenie R, Lopez-Bernal J, Cottrell S, Bucholc M, Kissling E; European IVE group; Members of the European IVE group. Rose AM, et al. Euro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Euro Surveill. 2025. PMID: 39980423 Free PMC article.
Characterization of a suspension Vero cell line for viral vaccine production.
Bourigault L, Bresson C, Jean C, Chevalard C, Kloutz M, Soulet D, Pelissier F, Richard S, Bassard I, Sève N, Charretier C, Pain B. Bourigault L, et al. Among authors: seve n. NPJ Vaccines. 2025 Jun 5;10(1):114. doi: 10.1038/s41541-025-01157-2. NPJ Vaccines. 2025. PMID: 40473628 Free PMC article.
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network.
Laniece Delaunay C, Verdasca N, Monge S, Domegan L, Sève N, Buda S, Meijer A, Lucaccioni H, López Torrijos M, McKenna A, Enouf V, Dürrwald R, In't Velt E, de Valcárcel Laiglesia MÁ, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinarić I, Túri G, Rodrigues AP, Martínez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: seve n. Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.70120. Influenza Other Respir Viruses. 2025. PMID: 40395132 Free PMC article.
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.
Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Domegan L, Hooiveld M, Oroszi B, Martínez-Baz I, Guiomar R, Latorre-Margalef N, Mlinarić I, Lazar M, Giménez Duran J, Dürrwald R, Enouf V, McKenna A, de Lange M, Túri G, Trobajo-Sanmartín C, Gomez V, Samuelsson Hagey T, Višekruna Vučina V, Cherciu MC, García Vazquez M, Erdwiens A, Masse S, Bennett C, Meijer A, Kristóf K, Castilla J, Rodrigues AP, Kurečić Filipović S, Ivanciuc AE, Bacci S, Kaczmarek M; European primary care VE group. Kissling E, et al. Among authors: seve n. Euro Surveill. 2025 Jun;30(23):2500011. doi: 10.2807/1560-7917.ES.2025.30.23.2500011. Euro Surveill. 2025. PMID: 40511473 Free PMC article.
G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M, Moreno N, Guinchard F, Nicolai MC, Niogret-Siohan E, Sève N, Manin C, Guinet-Morlot F, Riou P. Chabaud-Riou M, et al. Among authors: seve n. Biologicals. 2017 Mar;46:124-129. doi: 10.1016/j.biologicals.2017.02.002. Epub 2017 Feb 14. Biologicals. 2017. PMID: 28214171 Free article.
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Merdrignac L, et al. Among authors: seve n. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009. Influenza Other Respir Viruses. 2024. PMID: 39523781 Free PMC article.
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Laniece Delaunay C, et al. Among authors: seve n. JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258. JAMA Netw Open. 2024. PMID: 38949812 Free PMC article.
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: seve n. Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839521 Free PMC article.
Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Martínez-Baz I, Ilić M, Carnahan AS, Mihai ME, Martínez A, Goerlitz L, Enouf V, Horváth JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmartín C, Mlinarić I, Latorre-Margalef N, Ivanciuc A, Lopez A, Dürrwald R, Falchi A, Túri G, Meijer A, Melo A, O'Donnell J, Castilla J, Vučina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, Kissling E; VEBIS study team. Maurel M, et al. Among authors: seve n. Influenza Other Respir Viruses. 2024 Jan 10;18(1):e13243. doi: 10.1111/irv.13243. eCollection 2024 Jan. Influenza Other Respir Viruses. 2024. PMID: 38204584 Free PMC article.
17 results